<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00837759</url>
  </required_header>
  <id_info>
    <org_study_id>090056</org_study_id>
    <secondary_id>09-DK-0056</secondary_id>
    <secondary_id>09-DK-0056</secondary_id>
    <nct_id>NCT00837759</nct_id>
  </id_info>
  <brief_title>Novel Therapy to Preserve Beta Cell Function in New Onset Type 1 Diabetes</brief_title>
  <official_title>Novel Therapy Combining Regenerative Stimuli Immunomodulation to Preserve Beta Cell Function in New Onset Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

        -  Type 1 diabetes (T1D) occurs when the immune system attacks insulin-producing cells
           (beta cells) in the pancreas, resulting in their death.

        -  Insulin injections currently are the best method for controlling blood sugar in
           individuals with T1D. However, animal studies have shown that the drugs sitagliptin and
           lansoprazole can help reverse beta cell damage or develop new beta cells. In addition,
           Diamyd has been shown to weaken the immune process that attacks pancreatic beta cells.

      Objectives:

        -  To find out whether a combination treatment of sitagliptin, lansoprazole, and Diamyd
           will help maintain functioning beta cells and/or cause new beta cells to form.

        -  To determine how the drug combination affects insulin doses and blood sugar control.

        -  To determine whether the drug combination affects the immune response involved in T1D.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 1 diabetes (T1D) is the end result of immune mediated beta-cell destruction. It is
      generally accepted that at the time of T1D is diagnosed, an individual has lost most (60-80%)
      of his/her beta cell function. The loss of insulin-producing beta cells is believed to occur
      over a period of months to years and individuals can retain some endogenous insulin
      production even years after clinical diagnosis of diabetes. The presence of residual beta
      cell mass may signify a complex interplay between the auto-destructive immune response and
      the capacity for limited beta cell regeneration. When initiated at T1D onset,
      immunosuppression has been shown to preserve beta cell function, but with significant and
      limiting toxicities. Selectively targeting the pathogenic T-cells involved in T1D development
      and progression could achieve the same objective with less toxicity. Various studies of the
      non-obese diabetic (NOD) mouse model of spontaneous autoimmune diabetes have demonstrated
      that administering glutamic acid decarboxylase (GAD65), a beta cell autoantigen, can prevent
      the immune destruction and delay or prevent diabetes onset. Preclinical studies have also
      identified several growth factors, including epidermal growth factor (EGF), glucagon-like
      peptide 1 (GLP-1), and gastrin, that appear to promote beta cell proliferation. We seek to
      test the potential for preserving beta cell function early in the disease course of T1D by
      combining antigen-specific immunomodulation with regenerative stimuli.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Changes to study personnel.
  </why_stopped>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in C-peptide</measure>
    <time_frame>6 months following the protocol subject's randomization/treatment initiation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glycemia Control (Change in HbA1c Level)</measure>
    <time_frame>6 months following the protocol subject's randomization/treatment initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Insulin Dose</measure>
    <time_frame>6 months following the protocol subject's randomization/treatment initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Anti-GAD Autoantibody Titers</measure>
    <time_frame>6 months following the protocol subject's randomization/treatment initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Anti-IA2 Titer</measure>
    <time_frame>6 months following the protocol subject's randomization/treatment initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ZnT8 Autoantibody Titer</measure>
    <time_frame>6 months following the protocol subject's randomization/treatment initiation</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Diabetes Mellitus Type 1</condition>
  <condition>Autoimmune Diabetes</condition>
  <arm_group>
    <arm_group_label>T1D group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This study was terminated prior to full subject accrual because of changes to study personnel. The original study design was changed from a double-blind, placebo-controlled study to an open-label pilot study in order to collect safety data on enrolled subjects prior to study termination.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <arm_group_label>T1D group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lansoprazole</intervention_name>
    <arm_group_label>T1D group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <arm_group_label>T1D group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Diamyd</intervention_name>
    <arm_group_label>T1D group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GAD65 (Diamyd)</intervention_name>
    <arm_group_label>T1D group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

               1. Recently diagnosed (within the preceding 4 months of screening) diabetes
                  clinically consistent with T1D:

                  A. Positive for anti-GAD antibody.

                  B. BMI between 19 and 28 kg/m2; for those between the ages of 16 to 18, the BMI
                  must be within 10th to 90th percentile for the age.

               2. Ages between 16 and 30 years, inclusive

               3. Random plasma C-peptide level of equal to or greater than 0.20 nmol/L

               4. Willingness and ability to institute intensive insulin-based glucose management.

        EXCLUSION CRITERIA:

          1. Diabetic nephropathy with a creatinine clearance less than 60 cc/min or 24 hour urine
             albumin greater than 300 mg

          2. Insulin requirements greater than 0.8 units/kg/day at the end of the run-in period

          3. Regular use of a proton pump inhibitor within 3 months of enrollment

          4. Use of GLP-1R agonist or DPP-4 inhibitor within 6 months prior to enrollment

          5. Use of immunosuppressive therapy in the preceding 12 months

          6. Evidence of chronic infection, for example, known human immunodeficiency virus (HIV)
             or hepatitis

          7. History of any malignancy other than a treated basal or squamous skin cancer

          8. Any chronic medical condition to unduly increase risk for the potential enrollee as
             judged by study investigators

          9. Pregnancy, breastfeeding or planned pregnancy within two years, women of reproductive
             age not using an effective mode of contraception and unwilling to continue adequate
             contraception until 1 year after the last study drug administration

         10. Any other co-existing condition/circumstances that would make patient unsuitable to
             participate in the study, as deemed by the investigators. For example, study
             investigators would exclude any potential candidate with any of the following (but the
             list is not inclusive):

        A. Clinically significant past history of an acute reaction to vaccines or other drugs

        B. Recent participation in other clinical trials with a new chemical entity

        C. A history of alcohol or drug abuse

        D. Significant neurological conditions like epilepsy, head trauma, or cerebrovascular
        accidents

        E. Individuals with significant gastrointestinal disorders determined by the study
        investigators to influence either study safety or data interpretation. Such conditions
        include but are not limited to gastroparesis and gastric bypass surgery

        F. Individuals with conditions prone to hypergastrinemia (Zollinger-Ellison syndrome, use
        of histamine-2 receptor blockers) or hypogastrinemia (gastric surgery).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Balow James, MD</last_name>
    <role>Study Director</role>
    <affiliation>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bach JF, Chatenoud L. Tolerance to islet autoantigens in type 1 diabetes. Annu Rev Immunol. 2001;19:131-61. Review.</citation>
    <PMID>11244033</PMID>
  </reference>
  <reference>
    <citation>Lernmark A, BÃ¤rmeier H, Dube S, Hagopian W, Karlsen A, Wassmuth R. Autoimmunity of diabetes. Endocrinol Metab Clin North Am. 1991 Sep;20(3):589-617. Review.</citation>
    <PMID>1935920</PMID>
  </reference>
  <reference>
    <citation>Mathis D, Vence L, Benoist C. beta-Cell death during progression to diabetes. Nature. 2001 Dec 13;414(6865):792-8. Review.</citation>
    <PMID>11742411</PMID>
  </reference>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2009</study_first_submitted>
  <study_first_submitted_qc>February 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2009</study_first_posted>
  <results_first_submitted>March 24, 2012</results_first_submitted>
  <results_first_submitted_qc>September 24, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 24, 2012</results_first_posted>
  <last_update_submitted>December 31, 2012</last_update_submitted>
  <last_update_submitted_qc>December 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 3, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</investigator_affiliation>
    <investigator_full_name>James Balow</investigator_full_name>
    <investigator_title>Clinical Director Intramural NIDDK</investigator_title>
  </responsible_party>
  <keyword>Type I Diabetes</keyword>
  <keyword>Preserve Beta Cell Function</keyword>
  <keyword>Sitagliptin</keyword>
  <keyword>Lansoprazole</keyword>
  <keyword>GAD65 (Diamyd)</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Type 1 Diabetes</keyword>
  <keyword>T1DM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Dexlansoprazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>T1D Group</title>
          <description>Subjects between the ages of 16 and 30 years, with T1D diagnosed within the preceding 6 month period, and with measurable circulating C-peptide levels.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>T1D Group</title>
          <description>Subjects between the ages of 16 and 30 years, with T1D diagnosed within the preceding 6 month period, and with measurable circulating C-peptide levels.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.9" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in C-peptide</title>
        <time_frame>6 months following the protocol subject's randomization/treatment initiation</time_frame>
        <population>Only 3 subjects completed study</population>
        <group_list>
          <group group_id="O1">
            <title>T1D Group</title>
            <description>Subjects between the ages of 16 and 30 years, with T1D diagnosed within the preceding 6 month period, and with measurable circulating C-peptide levels.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in C-peptide</title>
          <population>Only 3 subjects completed study</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.51" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glycemia Control (Change in HbA1c Level)</title>
        <time_frame>6 months following the protocol subject's randomization/treatment initiation</time_frame>
        <population>Only 3 subjects completed study</population>
        <group_list>
          <group group_id="O1">
            <title>T1D Group</title>
            <description>Subjects between the ages of 16 and 30 years, with T1D diagnosed within the preceding 6 month period, and with measurable circulating C-peptide levels.</description>
          </group>
        </group_list>
        <measure>
          <title>Glycemia Control (Change in HbA1c Level)</title>
          <population>Only 3 subjects completed study</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.17" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Insulin Dose</title>
        <time_frame>6 months following the protocol subject's randomization/treatment initiation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>T1D Group</title>
            <description>Subjects between the ages of 16 and 30 years, with T1D diagnosed within the preceding 6 month period, and with measurable circulating C-peptide levels.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Insulin Dose</title>
          <units>U/kg/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Anti-GAD Autoantibody Titers</title>
        <time_frame>6 months following the protocol subject's randomization/treatment initiation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>T1D Group</title>
            <description>Subjects between the ages of 16 and 30 years, with T1D diagnosed within the preceding 6 month period, and with measurable circulating C-peptide levels.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Anti-GAD Autoantibody Titers</title>
          <units>Titers</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119278" spread="174649"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Anti-IA2 Titer</title>
        <time_frame>6 months following the protocol subject's randomization/treatment initiation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>T1D Group</title>
            <description>Subjects between the ages of 16 and 30 years, with T1D diagnosed within the preceding 6 month period, and with measurable circulating C-peptide levels.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Anti-IA2 Titer</title>
          <units>Titers</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29212" spread="49956"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in ZnT8 Autoantibody Titer</title>
        <time_frame>6 months following the protocol subject's randomization/treatment initiation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>T1D Group</title>
            <description>Subjects between the ages of 16 and 30 years, with T1D diagnosed within the preceding 6 month period, and with measurable circulating C-peptide levels.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in ZnT8 Autoantibody Titer</title>
          <units>Titers</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.11" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>T1D Group</title>
          <description>Subjects between the ages of 16 and 30 years, with T1D diagnosed within the preceding 6 month period, and with measurable circulating C-peptide levels.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Warts</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemic events</sub_title>
                <description>According to the protocol, hypoglycemia adverse events are described as follows:
Mild= BG &lt; 65 mg/dL Moderate = BG &lt; 54 mg/dL &amp; symptomatic Severe = patient required assistance to obtain treatment for the event.</description>
                <counts group_id="E1" events="104" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Rana Malek</name_or_title>
      <organization>NIDDK, National Institutes of Health</organization>
      <phone>3015945288</phone>
      <email>malekr@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

